EVD Drainage Data and Intracranial Pressure (ICP) Measurements
Recruiting now · Not applicable
Conditions studied: Hydrocephalus
In brief
Rhaeos, Inc. is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now. FlowSense, is a wireless, noninvasive thermal flow sensor that can be mounted on a patient's neck overlying the shunt to detect the presence and magnitude of CSF. Similar in size to a bandage, it is composed of soft, silicone with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. With FlowSense, monitoring of shunt function can occur in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.
Key facts
- Study ID
- NCT05546996
- Run by
- Baylor College of Medicine
- People needed
- 24
- Starts
- 2023-07-11
- Expected to finish
- 2027-01-30
- Last updated by the study team
- 2026-03-25
Who can join
Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with one or more existing external ventricular drains (EVDs).
You may not qualify if…
- Patients with no external ventricular drains (EVDs).
Where it is running
- Texas Children's Hospital — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.